The small cell lung cancer market stands at an inflection point, with ifinatamab deruxtecan representing the vanguard of a ...

Akeso and Summit Therapeutics' PD-1xVEGF drug has delivered its first overall survival win in a phase 3 trial. Fosun Pharma ...

A new report paints a grim outlook for the Massachusetts biotech industry, as venture investment fell 17% in the first half ...

Akeso, a Chinese biotech with a drug positioned to rival Merck’s Keytruda, reported that its lung cancer therapy can improve ...

Survival outcomes for patients with extensive stage small cell lung cancer (ES-SCLC) treated with consolidative thoracic radiation therapy (cTRT) and chemoimmunotherapy (CIT): A population level study ...

For the first time, Akeso and Summit Therapeutics’ closely watched PD-1xVEGF bispecific antibody has shown that it can extend ...

National registry study finds overall survival improved across the board after the introduction of immune checkpoint ...

Roche said Tecentriq combined with lurbinectedin shows significant survival benefits for patients with extensive-stage small cell lung cancer. The Swiss pharmaceutical company said Tuesday that ...

Lung cancer may be curable, depending on a number of factors, including your age, health, stage of cancer, and how it responds to treatment.

Efficacy and safety of combination therapy versus monotherapy in advanced non-small cell lung cancer: A meta-analysis of overall survival and progression-free survival. Dynamic combined monitoring of ...

Despite complete surgical resection, a substantial proportion of patients with early-stage non-small-cell lung cancer (NSCLC) ...

Memgen, Inc., a clinical-stage biotechnology company developing oncolytic immunotherapy for solid tumors, today announced the dosing of the first patient in its Phase 1 combination cohort evaluating ...